Patient Characteristics, Clinical Diagnosis, and Dual-Tracer PET/CT Diagnosis
| General marrow activity | SUVmax (FBLs) | No. of FBLs | PET/CT diagnosis | |||||||||
| Patient no. | Sex | Age (y) | M-protein | Clinical diagnosis | 11C-ACT | 18F-FDG | 11C-ACT | 18F-FDG | 11C-ACT | 18F-FDG | 11C-ACT | 18F-FDG |
| 1 | M | 82 | IgG κ | III | 5.49 (+) | 3.60 (+) | 15.7 | — | 28 | 0 | F + D | D |
| 2 | M | 61 | LC κ | III | 5.12 (+) | 2.23 (−) | — | — | 0 | 0 | D | N |
| 3 | M | 65 | LC λ | III | 7.88 (+) | 1.84 (−) | — | — | 0 | 0 | D | N |
| 4 | F | 57 | IgD λ | III | 9.90 (+) | 6.03 (+) | — | — | 0 | 0 | D | D |
| 5 | F | 76 | LC κ | II | 4.57 (+) | 3.19 (+) | 12.2 | 8.7 | 50 | 26 | F + D | F + D |
| 6 | M | 75 | IgG κ | II | 5.50 (+) | 2.70 (−) | — | — | 0 | 0 | D | N |
| 7 | F | 87 | IgG κ | II | 8.17 (+) | 6.70 (+) | 11.2 | 12.5 | 11 | 8 | F + D | F + D |
| 8 | M | 62 | IgA κ | I | 4.10 (+) | 2.91 (−) | — | — | 0 | 0 | D | N |
| 9 | M | 62 | LC κ | I | 7.15 (+) | 3.78 (+) | 12.6 | — | 1 | 0 | F + D | D |
| 10 | F | 69 | LC λ | I | 4.04 (+) | 1.93 (−) | — | — | 0 | 0 | D | N |
| 11 | M | 66 | IgA κ | I | 8.27 (+) | 4.26 (+) | 13.3 | — | 5 | 0 | F + D | D |
| 12 | F | 69 | IgA λ | I | 3.94 (+) | 2.96 (−) | — | — | 0 | 0 | D | N |
| 13 | F | 52 | IgG κ | I | 4.43 (+) | 5.02 (+) | 4.5 | 6.7 | 2 | 4 | F + D | F + D |
| 14 | M | 57 | IgA λ | I | 4.95 (+) | 4.78 (+) | 9.5 | 4.6 | 8 | 1 | F + D | F + D |
| 15 | M | 89 | IgA κ | I | 4.42 (+) | 3.03 (+) | 18.2 | 4.9 | 24 | 12 | F + D | F + D |
| 16 | F | 56 | IgG κ | I | 3.83 (+) | 5.92 (+) | 16.3 | 21.0 | 6 | 6 | F + D | F + D |
| 17 | F | 60 | LC λ | I | 4.11 (+) | 3.15 (+) | 20.8 | 8.9 | 1 | 1 | F + D | F + D |
| 18 | M | 63 | IgG κ | I | 4.95 (+) | 2.93 (−) | 13.4 | 7.1 | 3 | 2 | F + D | F |
| 19 | M | 57 | LC λ | I | 3.62 (−) | 2.67 (−) | 20.5 | 11.6 | 11 | 11 | F | F |
| 20 | M | 64 | LC κ | I | 5.77 (+) | 2.10 (−) | 13.4 | 6.3 | 4 | 3 | F + D | F |
| 21 | F | 48 | LC κ | I | 4.82 (+) | 2.53 (−) | — | — | 0 | 0 | D | N |
| 22 | M | 80 | IgG λ | I | 4.36 (+) | 3.67 (+) | — | — | 0 | 0 | D | D |
| 23 | F | 58 | IgG κ | I | 2.62 (−) | 2.24 (−) | — | — | 0 | 0 | N | N |
| 24 | F | 64 | IgG κ | I | 3.09 (−) | 2.91 (−) | — | — | 0 | 0 | N | N |
| 25 | M | 61 | IgG λ | I | 3.77 (−) | 2.20 (−) | — | — | 0 | 0 | N | N |
| 26 | M | 78 | IgA κ | I | 3.04 (−) | 2.98 (−) | — | — | 0 | 0 | N | N |
| 27 | F | 48 | IgA λ | I (SMM) | 2.78 (−) | 2.56 (−) | — | — | 0 | 0 | N | N |
| 28 | M | 72 | IgG κ | I (SMM) | 3.78 (−) | 1.64 (−) | — | — | 0 | 0 | N | N |
| 29 | M | 49 | IgG κ | I (SMM) | 3.67 (−) | 2.71 (−) | — | — | 0 | 0 | N | N |
| 30 | M | 74 | IgG λ | I (SMM) | 3.11 (−) | 2.34 (−) | — | — | 0 | 0 | N | N |
| 31 | M | 51 | IgG κ | I (SMM) | 2.91 (−) | 2.99 (−) | — | — | 0 | 0 | N | N |
| 32 | M | 43 | LC κ | MGUS | 2.21 (−) | 1.79 (−) | — | — | 0 | 0 | N | N |
| 33 | F | 60 | IgG λ | MGUS | 2.62 (−) | 2.44 (−) | — | — | 0 | 0 | N | N |
| 34 | F | 44 | IgG κ | MGUS | 3.11 (−) | 3.29 (+) | — | — | 0 | 0 | N | D |
| 35 | F | 60 | IgG λ | MGUS | 3.75 (−) | 3.62 (+) | — | — | 0 | 0 | N | D |
M-protein = monoclonal protein; FBL = focal bone lesion; ACT = acetate; F = focal; D = diffuse; LC = light chain; N = negative.